Brain disease device and software market seen reaching $25.21 billion by 2030

The global market for brain disease devices and software is projected to grow from $15.59 billion in 2025 to $25.21 billion by 2030, driven by rising neurological disorders, AI-enabled tools and remote monitoring. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The market sits at the center of rising demand for better diagnosis, monitoring and treatment of neurological conditions. - Growth in wearable devices, AI tools and remote care could change how brain diseases are managed outside traditional imaging and hospital settings. - Rising dementia and other neurological cases increase pressure on health systems to adopt earlier detection and ongoing monitoring tools.

What happened: - The Business Research Company released its 2026 report on the brain disease device and software market on July 29, 2026. - The report estimates the market will rise from $15.59 billion in 2025 to $17.2 billion in 2026. - The report forecasts the market will reach $25.21 billion by 2030. - The report projects a 10.3% CAGR from 2025 to 2026 and a 10.0% CAGR from 2026 to 2030.

The details: - The report links near-term growth to limited availability of diagnostic tools, rising neurological disorder cases, expanding hospital and clinic infrastructure, early telemedicine adoption and continued reliance on traditional brain imaging. - The forecast period is shaped by advances in wearable and AI-powered devices, neurorehabilitation technology, home care, remote monitoring and brain data management software. - The report also points to expanding research in neuroinformatics and cognitive assessment technologies. - Anticipated trends include broader use of neurostimulation and brain monitoring devices, deeper telemedicine integration, more cognitive assessment and neurofeedback software, personalized treatment approaches and more neuroimaging combined with data analytics. - The market covers devices and software used to diagnose, track and manage neurological conditions and brain-related diseases. - These tools are designed to improve patient care by detecting abnormalities, guiding targeted therapies and supporting continuous monitoring. - In July 2024, the UK National Health Service reported 487,432 dementia patients as of June 30, 2024, up 3,155 from the prior month.

Between the lines: - The forecast suggests brain health is moving from a specialty imaging problem toward a broader digital health category. - AI and analytics appear to be shifting from supporting roles to core tools for diagnosis and monitoring. - The dementia data underscores a wider demographic and clinical burden that favors scalable software-based management. - North America’s lead in 2025 reflects mature healthcare infrastructure and earlier technology adoption. - Asia-Pacific is expected to be the fastest-growing region through the forecast period, signaling widening demand outside the largest established markets.

What's next: - The report expects continued growth as neurostimulation, remote monitoring and personalized treatment tools gain wider use. - Expansion in neuroinformatics and cognitive assessment research is likely to influence the next wave of product development. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics and updated trend analysis. - The company also offers a free sample of the report and the full market report through its website.